Everett Harris & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $307K | Hold |
5,853
| – | – | ﹤0.01% | 255 |
|
|
2026
Q1 | $323K | Sell |
5,853
-800
| -12% | -$43.4K | ﹤0.01% | 264 |
|
|
2025
Q4 | $326K | Hold |
6,653
| – | – | ﹤0.01% | 270 |
|
|
2025
Q3 | $287K | Hold |
6,653
| – | – | ﹤0.01% | 278 |
|
|
2025
Q2 | $255K | Sell |
6,653
-23
| -0.3% | -$879 | ﹤0.01% | 289 |
|
|
2025
Q1 | $259K | Sell |
6,676
-720
| -10% | -$26.4K | ﹤0.01% | 281 |
|
|
2024
Q4 | $250K | Hold |
7,396
| – | – | ﹤0.01% | 264 |
|
|
2024
Q3 | $302K | Hold |
7,396
| – | – | ﹤0.01% | 233 |
|
|
2024
Q2 | $285K | Hold |
7,396
| – | – | ﹤0.01% | 235 |
|
|
2024
Q1 | $317K | Sell |
7,396
-2,272
| -24% | -$93.7K | ﹤0.01% | 217 |
|
|
2023
Q4 | $358K | Sell |
9,668
-503
| -5% | -$18.1K | 0.01% | 207 |
|
|
2023
Q3 | $369K | Hold |
10,171
| – | – | 0.01% | 195 |
|
|
2023
Q2 | $362K | Hold |
10,171
| – | – | 0.01% | 202 |
|
|
2023
Q1 | $362K | Sell |
10,171
-640
| -6% | -$22.4K | 0.01% | 192 |
|
|
2022
Q4 | $380K | Hold |
10,811
| – | – | 0.01% | 194 |
|
|
2022
Q3 | $318K | Sell |
10,811
-26
| -0.2% | -$985 | 0.01% | 203 |
|
|
2022
Q2 | $590K | Hold |
10,837
| – | – | 0.01% | 161 |
|
|
2022
Q1 | $590K | Hold |
10,837
| – | – | 0.01% | 175 |
|
|
2021
Q4 | $597K | Hold |
10,837
| – | – | 0.01% | 175 |
|
|
2021
Q3 | $518K | Hold |
10,837
| – | – | 0.01% | 179 |
|
|
2021
Q2 | $539K | Sell |
10,837
-95
| -0.9% | -$4.57K | 0.01% | 177 |
|
|
2021
Q1 | $488K | Sell |
10,932
-119
| -1% | -$5.4K | 0.01% | 178 |
|
|
2020
Q4 | $508K | Buy |
11,051
+449
| +4% | +$20.6K | 0.01% | 171 |
|
|
2020
Q3 | $499K | Hold |
10,602
| – | – | 0.01% | 164 |
|
|
2020
Q2 | $541K | Hold |
10,602
| – | – | 0.01% | 154 |
|
|
2020
Q1 | $502K | Buy |
10,602
+2,408
| +29% | +$128K | 0.01% | 152 |
|
|
2019
Q4 | $481K | Hold |
8,194
| – | – | 0.01% | 185 |
|
|
2019
Q3 | $437K | Hold |
8,194
| – | – | 0.01% | 179 |
|
|
2019
Q2 | $410K | Buy |
8,194
+1,962
| +31% | +$98.5K | 0.01% | 189 |
|
|
2019
Q1 | $326K | Hold |
6,232
| – | – | 0.01% | 200 |
|
|
2018
Q4 | $298K | Sell |
6,232
-320
| -5% | -$15.8K | 0.01% | 200 |
|
|
2018
Q3 | $329K | Sell |
6,552
-60
| -0.9% | -$3.05K | 0.01% | 203 |
|
|
2018
Q2 | $333K | Buy |
6,612
+320
| +5% | +$16.1K | 0.01% | 199 |
|
|
2018
Q1 | $307K | Buy |
+6,292
| New | +$293K | 0.01% | 202 |
|
Other funds holding GSK
JEST
Everett Harris & Co's GSK Position: Q2 2026 in Review
Everett Harris & Co held its GSK (GSK) position steady in Q2 2026 at 5,853 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #255.
Everett Harris & Co first reported a position in GSK in Q1 2018 and has held it in 34 quarters since. The position peaked at $597K in Q4 2021. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Everett Harris & Co held 5,853 shares of GSK worth $307K as of Q2 2026.
- Everett Harris & Co left its GSK share count unchanged in Q2 2026.
- GSK made up ﹤0.01% of Everett Harris & Co's portfolio in Q2 2026, its #255 holding.
- Everett Harris & Co first reported a position in GSK in Q1 2018 and has held it in 34 quarters since.
- Everett Harris & Co's GSK position peaked at $597K in Q4 2021.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Everett Harris & Co's 13F filing for Q2 2026, filed 3 Aug 2026.